Search

Displaying results 3281 - 3290 of 8698 in total
  1. Drug

    Islatravir

    go.drugbank.com/drugs/DB15653
    ApprovedInvestigational

    [A275490, A275492] Because it is a substrate for deoxycytidine kinase (dCK), its efficacy can be compromised by co-administration with other dCK substrates like lamivudine or emtricitabine, which are consequently … Islatravir is a first-in-class, highly potent nucleoside reverse transcriptase translocation inhibitor (NRTTI) used in combination therapy for the treatment of HIV-1 infection.

  2. Drug

    Neisseria meningitidis serogroup B recombinant LP2086 A05 protein variant antigen

    go.drugbank.com/drugs/DB10284
    ApprovedInvestigational

    Neisseria meningitidis serogroup B recombinant lp2086 a05 protein variant antigen is a sterile vaccine for intramuscular injection indicated for the active immunization to prevent invasive disease caused

    Mixtures: TRUMENBA SUSPENSION FOR INJECTION IN SINGLE-DOSE PRE-FILLED SYRINGE 0.5ML
  3. Drug

    Omidubicel

    go.drugbank.com/drugs/DB17132
    ApprovedInvestigational

    [A258938,A258943,L46048] This type of cell therapy benefits patients that require stem cell transplantation as a treatment for blood cancers for whom a related or unrelated donor cannot be found due to … In this group of patients, umbilical cord blood can be used as an alternative cell source since there is a lower risk of graft failure or graft-versus-host disease, even with low-grade HLA-matching.

  4. Drug

    Methacholine

    go.drugbank.com/drugs/DB06709
    Approved

    [L31763] In patients with AHR, a lower dose of methacholine is required to induce bronchoconstriction, which forms the basis for the methacholine challenge test to diagnose AHR. … [A229598, A229603] Although the underlying pathology of AHR is complex, ASM contraction can be stimulated by cholinergic agonists that activate M<sub>3</sub> muscarinic receptors that stimulate ASM contraction

    Categories: Cholinergic Receptor Agonist
  5. Drug

    Pumactant

    go.drugbank.com/drugs/DB04955
    Experimental

    Pumactant is a synthetic surfactant used for treating respiratory distress syndrome in neonates. … It is a unique formulation of the naturally occurring phospholipids Dipalmitoylphosphatidycholine (DPPC) and Phosphatidyl Glycerol (PG).

  6. Drug

    Oleic Acid

    go.drugbank.com/drugs/DB04224
    ApprovedInvestigationalVet approved

    An unsaturated fatty acid that is the most widely distributed and abundant fatty acid in nature. It is used commercially in the preparation of oleates and lotions, and as a pharmaceutical solvent.

    Mixtures: NEUROGAIN PB VEGICAP CAPSULE 500MG
  7. Drug

    Nateglinide

    go.drugbank.com/drugs/DB00731
    Approved

    Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). … Meglitnides may have a neutral effect on weight or cause a slight increase in weight.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  8. Drug

    Iproclozide

    go.drugbank.com/drugs/DB09247
    ApprovedWithdrawn

    Although it was employed as an antidepressant for a time, the fact that the agent is capable of causing fulminant hepatitis and that its use has been documented as the cause for at least three reported … Iproclozide is an irreversible and selective hydrazine class based monoamine oxidase inhibitor (MAOI).

  9. Drug

    Poractant alfa

    go.drugbank.com/drugs/DB09113
    ApprovedInvestigational

    It is used to treat Respiratory Distress Syndrome (RDS) in premature infants with an endogenous pulmonary surfactant deficiency. … Poractant alfa is an extract of natural porcine lung surfactant consisting of 99% polar lipids (mainly phospholipids) and 1% hydrophobic low molecular weight proteins (surfactant associated proteins SP-B

    Products: Curosurf 120 mg - Suspension zur endotracheopulmonalen Instillation, Curosurf 240 mg - Suspension zur endotracheopulmonalen Instillation
  10. Drug

    Pirtobrutinib

    go.drugbank.com/drugs/DB17472
    ApprovedInvestigational

    [A256758,A256773,L44863] However, other mutations may confer resistance to non-covalent BTK inhibitors such as pirtobrutinib. … Although the mechanisms of resistance to covalent BTK inhibitors have not been fully elucidated, it appears that the presence of Cys481 mutations is the most common reason for resistance to covalent BTK

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates